Epstein-Barr/JJ
virus/NN
nuclear/JJ
protein/NN
2/CD
transactivation/NN
of/IN
the/DT
latent/JJ
membrane/NN
protein/NN
1/CD
promoter/NN
is/VBZ
mediated/VBN
by/IN
J/NN
kappa/NN
and/CC
PU.1/NN
./.

Expression/NN
of/IN
the/DT
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
latent/JJ
membrane/NN
protein/NN
1/CD
(/(
LMP-1/NN
)/)
oncogene/NN
is/VBZ
regulated/VBN
by/IN
the/DT
EBV/NN
nuclear/JJ
protein/NN
2/CD
(/(
EBNA-2/NN
)/)
transactivator/NN
./.
=====
EBNA-2/NN
is/VBZ
known/VBN
to/TO
interact/VB
with/IN
the/DT
cellular/JJ
DNA-binding/JJ
protein/NN
J/NN
kappa/NN
and/CC
is/VBZ
recruited/VBN
to/TO
promoters/NNS
containing/VBG
the/DT
GTGGGAA/NN
J/NN
kappa/NN
recognition/NN
sequence/NN
./.
=====
The/DT
minimal/JJ
EBNA-2-responsive/JJ
LMP-1/NN
promoter/NN
includes/VBZ
one/CD
J/NN
kappa-binding/JJ
site/NN
,/,
and/CC
we/PRP
now/RB
show/VBP
that/IN
mutation/NN
of/IN
that/DT
site/NN
,/,
such/JJ
that/IN
J/NN
kappa/NN
can/MD
not/RB
bind/VB
,/,
reduces/VBZ
EBNA-2/NN
responsiveness/NN
by/IN
60/CD
%/NN
./.
=====
To/TO
identify/VB
other/JJ
factors/NNS
which/WDT
interact/VBP
with/IN
the/DT
LMP-1/NN
EBNA-2/NN
response/NN
element/NN
(/(
E2RE/NN
)/)
,/,
a/DT
-236/-145/JJ
minimal/JJ
E2RE/NN
was/VBD
used/VBN
as/IN
a/DT
probe/NN
in/IN
an/DT
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
./.
=====
The/DT
previously/RB
characterized/VBN
factors/NNS
J/NN
kappa/NN
,/,
PU.1/NN
,/,
and/CC
AML1/NN
bind/VBP
to/TO
the/DT
LMP-1/NN
E2RE/NN
,/,
along/IN
with/IN
six/CD
other/JJ
unidentified/JJ
factors/NNS
(/(
LBF2/NN
to/TO
LBF7/NN
)/)
./.
=====
Binding/VBG
sites/NNS
were/VBD
mapped/VBN
for/IN
each/DT
factor/NN
./.
=====
LBF4/NN
is/VBZ
B-/NN
and/CC
T-cell/NN
specific/JJ
and/CC
recognizes/VBZ
the/DT
PU.1/NN
GGAA/NN
core/NN
sequence/NN
as/IN
shown/VBN
by/IN
methylation/NN
interference/NN
./.
=====
LBF4/NN
has/VBZ
a/DT
molecular/JJ
mass/NN
of/IN
105/CD
kDa/NN
and/CC
is/VBZ
probably/RB
unrelated/JJ
to/TO
PU.1/NN
./.
=====
LBF2/NN
was/VBD
found/VBN
only/RB
in/IN
epithelial/JJ
cell/NN
lines/NNS
,/,
whereas/IN
LBF3/NN
,/,
LBF5/NN
,/,
LBF6/NN
,/,
and/CC
LBF7/NN
were/VBD
not/RB
cell/NN
type/NN
specific/JJ
./.
=====
Mutations/NNS
of/IN
the/DT
AML1-/NN
or/CC
LBF4-binding/JJ
sites/NNS
had/VBD
no/DT
effect/NN
on/IN
EBNA-2/NN
transactivation/NN
,/,
whereas/IN
mutation/NN
of/IN
the/DT
PU.1-binding/JJ
site/NN
completely/RB
eliminated/VBD
EBNA-2/NN
responses/NNS
./.
=====
A/DT
gst-EBNA-2/NN
fusion/NN
protein/NN
specifically/RB
depleted/VBD
PU.1/NN
from/IN
nuclear/JJ
extracts/NNS
and/CC
bound/VBD
in/FW
vitro/FW
translated/VBN
PU.1/NN
,/,
providing/VBG
biochemical/JJ
evidence/NN
for/IN
a/DT
direct/JJ
EBNA-2-PU.1/JJ
interaction/NN
./.
=====
Thus/RB
,/,
EBNA-2/NN
transactivation/NN
of/IN
the/DT
LMP-1/NN
promoter/NN
is/VBZ
dependent/JJ
on/IN
interaction/NN
with/IN
at/IN
least/JJS
two/CD
distinct/JJ
sequence-specific/JJ
DNA-binding/JJ
proteins/NNS
,/,
J/NN
kappa/NN
and/CC
PU.1/NN
./.
=====
LBF3/NN
,/,
LBF5/NN
,/,
LBF6/NN
,/,
or/CC
LBF7/NN
may/MD
also/RB
be/VB
involved/VBN
,/,
since/IN
their/PRP$
binding/VBG
sites/NNS
also/RB
contribute/VBP
to/TO
EBNA-2/NN
responsiveness/NN
./.